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SUMMARY
Background
Many reports of autoimmune hepatitis (AIH) were written in the
‘pre-Hepatitis C era’ and data on the natural history are still incomplete.
Aim
To evaluate the clinical presentation and the natural history of type I
AIH.
Methods
Seventy-three consecutive patients with a regular follow-up of at
least 2 years were prospectively included in the study. The mean
follow-up was 91  61 months.
Results
Patients with ‘acute’ onset at presentation were significantly older
than patients with ‘chronic’ onset (P < 0.05) and had significantly
higher serum levels of transaminase, c-glutamyltransferase2 and biliru-
bin; Prothrombin time2,3 was significantly lower in the said group com-
pared with AIH patients with ‘chronic’ onset. In 4 of 63 (6.3%)
female patients, AIH had the onset during pregnancy; in all of them
the outcome of pregnancy was favourable. The major events during
the follow-up included oesophageal varices (n ¼ 9) and ascites (n ¼
4), and4 60 patients remained in remission while receiving immuno-
suppression. None of the patients died during the follow-up, but
seven patients were transplanted. The cumulative transplant-free
probability of survival was 73.5% at 280 months.
Conclusions
Elderly patients have more frequently an acute onset at presentation.
Survival in AIH is apparently good; with early diagnosis, and improved
medical therapy, liver transplantation for AIH will become a rare event
in future.
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INTRODUCTION
Autoimmune hepatitis (AIH) is a chronic liver disease
of unknown cause, which occurs in children and
adults of all ages.1 In the presence of a histological
picture of chronic hepatitis, diagnosis is based on
characteristic clinical and biochemical findings, circu-
lating autoantibodies and abnormal levels of serum
globulins.1 It is a rare disease, with an estimated pre-
valence of approximately 170 cases per 1 million in
northern Europe.2 On the basis of autoantibody pat-
tern, AIH can be classified into three types: type I
[characterized by antinuclear (ANA) and smooth mus-
cle (SMA)antibodies]; type II [characterized by the
presence of anti-liver-kidney microsomes type I5 (LKM-
I)] and type III [characterized by the positivity of sol-
uble liver antigen6 (SLA)].
A scoring system proposed by the International
Autoimmune Hepatitis Group (IAHG) to standardize
the diagnosis for clinical trials provides support for
diagnosing AIH.3
The introduction in the late 1960s and 1970s of
corticosteroid-based immunosuppressive regimens,
with or without azathioprine as a steroid-sparing
agent, dramatically improved the quality and length
of life. During the subsequent years, the standard
therapy for type I AIH with prednisolone or predni-
sone in monotherapy or in combination with
azathioprine has been adopted worldwide. Remission
of the disease is achieved on treatment in 65–80%
of patients.4–6 One study considered the long-term
follow-up of patients with maintenance therapy, with
azathioprine, as being successful in approximately
80% of patients.7 A recent paper included 205 white
North American patients with type I AIH evaluated
between 1975 and 2005 at the Mayo Clinic.8
Roughly, 50% of them have a follow-up of at least
5 years. The overall rate of remission during immu-
nosuppression ranged from 50% in younger to 61%
in elderly patients.
A clinical trial from Canada in a large cohort of
patients with AIH showed that patients who are
asymptomatic at presentation have a good prognosis
and may not require immunosuppressive therapy; cir-
rhosis on liver biopsy portends a poor prognosis in all
patients.9 On the contrary, another study from the
Mayo Clinic showed that histological cirrhosis does
not diminish survival expectations.10 However, stud-
ies on the natural history of AIH in Europe are still
lacking.
The aim of the present study was, therefore, to
evaluate the clinical presentation and the natural his-
tory of AIH.
MATERIALS AND METHODS
Patients
The study considered all patients consecutively diag-
nosed with type I AIH between 1981 and 2004 in three
Italian referring centres for AIH: University of Padova7 ,
Turin University and San Giovanni Rotondo Hospital.
All patients had a regular follow-up of at least 2 years.
Among them, 73 patients (63 females, 10 males, mean
age 47.7  17.9 years) were included.
The diagnosis of type I AIH was made by clinical,
immunological and histological grounds. All patients
had a positivity for ANA or antismooth muscle anti-
bodies (ASMA); SLA was negative in all patients. All
subjects were negative for HBV and HCV serum
markers.
Acute presentation was defined by the presence of
recent onset (<30 days) symptoms (jaundice and/or
fatigue and/or drowsiness) in conjunction with serum
alanine transferase levels higher than 10-fold the
upper normal limit). Most of these patients had been
originally admitted to an ‘infectious disease’ ward
with the diagnostic suspicion of acute viral hepatitis.
Patients with ‘chronic’ exhibited clinical and
biochemical features compatible with chronic liver
disorder. Symptoms had been persisting for at least
6 months and were usually minor and unspecific.
The revised scoring system for the diagnosis of AIH
was calculated according to the report of the IAHG.3
Evaluation of liver histology
All patients included in the study underwent liver
biopsy. Biopsy samples were examined in a blinded
fashion using codes by a dedicated pathologist. The
stains available included haematoxylin, stains for
connective tissue, iron and copper-associated protein.
The following histological features were recorded:
portal inflammation, interface hepatitis (piecemeal
necrosis), hepatocyte rosetting, ductular proliferation,
bile duct damage, lobular necrosis, bridging necrosis
and canalicular cholestasis. Liver biopsies of all indi-
viduals were graded and staged according to
the internationally recognized histological scoring
system.10
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Follow-up
The patients were followed up regularly every 4–
6 months by clinical and biochemical examination.
Biochemical parameters included AST, ALT, alkaline
phosphatase, immunoglobulins, bilirubin, red blood
cell, white blood cell and platelet counts, prothrombin
time and a-foetoprotein.
Liver ultrasound was performed every 12 months in
precirrhotic patients and every 6 months in patients
with cirrhosis. The mean follow-up was
91  61 months.
Treatment
All patients (with either ‘acute’ or ‘chronic’ onset) were
treated with prednisolone or prednisone (initial dosage
of 0.5 mg/kg/day) associated with steroid-sparing
azathioprine (initial dosage of 2 mg/kg/day) with a
tailored maintenance dosage of 10 mg/day of steroid
and 50–75 mg/day of azathioprine. Only one patient
experienced intolerance to azathioprine and received
prednisolone as monotherapy. Compliance with the
treatment and side effects were assessed by means of
personal interviews every 6 months.
Bone mineral density was assessed by dual-photon
X-ray absorptiometry at the lumbar spine every
2 years. Patients with osteoporosis received i.m. diso-
dium clodronate 100 mg every 10 days and calcium
plus vitamin D supplements.
Withdrawal of immunosuppressive therapy after
2 years on attainment of normal level of enzymes was
achieved in only one patient (a 69-year-old male), but
he also experienced a relapse within 6 months8 , and
immunosuppression was started again.
Laboratory methods
Autoantibodies (ASMA, ANA, AMA and LKM) were
tested by indirect immunofluorescence method using
normal human gastric mucosa and normal rat kidney
and liver. Sera were tested at an initial dilution of 1:5
and were considered to be positive when they pro-
duced a reaction at a dilution of ‡1:40. Antineutrophil
cytoplasmic antibodies (ANCA) were determined by
indirect immunofluorescence. The patient’s serum
(diluted 1:20, 1:40) was applied to neutrophils previ-
ously fixed in ethanol and incubated with F(ab)2 frag-
ment of rabbit anti-human immunoglobulin G chain
labelled with fluorescein isothiocyanate (Alifax Diag-
nostici, Padova, Italy). Immunofluorescent staining in
the perinuclear zone (p-ANCA) or cytoplasmic com-
partment (c-ANCA) in the 1:20 sample was taken as
positive.
Hepatitis B (HBsAg and anti-HBc) infection was
determined by ELISA using commercially available
kits (Abbott Laboratories, North Chicago, IL, USA).
Testing for anti-HCV was performed in duplicate
by second and third generation ELISA (Ortho Diag-
nostic system, Raritan, NJ, USA) and confirmed by
HCV-RNA detection using a commercially available
qualitative polymerase chain reaction assay (Ampli-
cor Monitor assay; Roche Diagnostic System,
Branchburg, NJ, USA). HCV testing in patients
enrolled before 1990 was performed on stored sera
during follow-up.
The other biochemical variables were assayed by
standard methods.
Statistical analysis
Quantitative data are expressed as median and range.
The t-test was used for quantitative data, Chi-squared
test for qualitative data and Wilcoxon test for matched
pairs. Survival was analysed according to the Kaplan–
Meier method and was assessed with the log-rank test.
Statistical analysis was performed using SPSS software
(SPSS, Chicago, IL, USA).
RESULTS
The clinical details of patients at presentation are sum-
marized in Table 1 (data are expressed as mean  s.d.).
Sixty-three patients were females. The mean age was
48.8  17.9 years. At presentation, a definite IAHG
pretherapy score was fulfilled by 48 patients (65.8%);
the remaining 24 patients had a probable diagnosis of
AIH (32.99%). Twenty-eight subjects (38.4%) had cir-
rhosis at presentation.
Patients with acute onset at presentation (n ¼ 27)
were significantly older than patients with chronic
onset (n ¼ 46) (56  20 vs. 45.5  15 years,
P < 0.05). Moreover, they exhibited significantly
higher levels of serum transaminases, GGT, total bilir-
ubin (P < 0.001) than patients with chronic onset.
They also exhibited significantly lower mean pro-
thrombin percentage (P < 0.001) and serum albumin
(P < 0.05) compared with the latter group (Table 2).
AIH scores or antibody profiles were not different
between the two groups.
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In the medical history of patients with acute onset,
we could identify the assumption of a drug that
appears as a ‘trigger agent’ for AIH in five subjects
(four of them were older than 65 years). The recorded
medications were trazodone in one, nimesulide in
three and thorvastatin in one.
Overall, 16 patients experienced the onset of AIH in
their geriatric life (>65 years) and 57 in adult life
(Table 3). Patients over 65 years had significantly
higher levels of both AST (P < 0.02) and GGT
(P < 0.01) than patients below 65 years of age. The
mean histological grade before treatment was similar
in the two groups of patients, while the histological
stage, an indicator of hepatic fibrosis, was significantly
higher in older patients compared with the patients
below 65 years of age (P < 0.003). The number of
patients with cirrhosis (i.e. stage 6 at presentation) was
10 (62.5%) in the >65 group and 18 (31.5%) in the
<65 group (P < 0.001) (Table 3).
As expected, 31 of 73 patients with type I AIH
(42.5%) had association with extrahepatic autoimmune
conditions. The most frequent condition was autoim-
mune thyroid dysfunction (23.3%) (Table 4).
Table 5 summarizes the relationship between AIH
and pregnancy. Of 63 females (6.3%), four had onset
of the disease during pregnancy, and the outcome of
pregnancy in these patients was favourable. The total
number of pregnancies was 94 (93.6%) before the
onset of the disease and 69 (6.4%) after the diagnosis of
AIH, during the pharmacological remission. During
pregnancy, immunosuppression was continued, but the
maintenance dosage was very low (5–7.510 mg/day of
prednisolone plus 50 mg/day of azathioprine). Among
these, two patients experienced miscarriage and the
remaining had a normal vaginal delivery. Overall no
alteration of the fertile life was noted. Particularly, the
mean age of menarche was 12.8  1.7 years and the
mean age of menopause was 50.5  3.8 years.
Follow-up
The mean follow-up was 91  61 months.
The major events in the group with AIH included
oesophageal varices (n ¼ 9) and ascites (n ¼ 4), and
60 patients remained in remission while receiving
immunosuppression (Table 6).
Table 1. Clinical details of patients at presentation
(mean  s.d.)
No. of patients 73
Age 48.8  17.9
Female (%) 86.3
AST (U/L) 469.9  467.9
ALT (U/L) 551.1  532.9
GGT (U/L) 142.0  110.0
ALP (U/L) 241.5  161.8
IgG (mg/dL) 2329.0  956.6
IgA (mg/dL) 318.9  194.2
IgM (mg/dL) 175.0  118.0
PT (%) 73.0  17.0
Serum albumin (g/L) 36.0  5.8
Total bilirubin (mg/dL) 2.8  4.0
Conjugated bilirubin (mg/dL) 1.8  3.0
ANA (‡1:40) (%) 24/73 (32.8)
SMA (‡1:40) (%) 17/73 (23.3)
ANA + SMA (‡1:40) (%) 32/73 (43.0)
Probable IAHG pretherapy score (%) 4 (5.4)
Definite IAHG pretherapy score (%) 69 (94.58)
ALT, alanine amino transferase; AST, aspartate amino trans-
ferase; GGT, c-glutamyl transferase; ALP, alkaline phospha-
tase; IgG, immunoglobulin G; IgA, immunoglobulin A;
IgM, immunoglobulin M; PT, prothrombin time.
Table 2. Clinical features of patients with acute onset and
chronic onset AIH (mean  s.d.)
Acute onset Chronic onset P-value
No. of patients 27 46 –
Age (mean  s.d.) 56.0  20.0 45.5  15.0 <0.05
Age >65 years (n) 11 (40%) 5 (11%) <0.005
Female (%) 88.9 84.8 –
AST (U/L) 796.2  528.4 299.7  326.4 <0.001
ALT (U/L) 901.0  579.7 368.5  405.4 <0.001
GGT (U/L) 203.9  138.9 109.4  74.1 <0.001
ALP (U/L) 266.7  124.9 228.4  177.9 N.S.
IgG (mg/dL) 2386.8  685.8 2298.7  1077.1 N.S.
IgA (mg/dL) 335.3  180.5 309.9  202.8 N.S.
IgM (mg/dL) 216.3  160.2 152.8  80.8 0.04
PT (%) 65.2  16.5 76.7  16.6 <0.001
Serum albumin
(g/L)
33.3  5.2 30.6  15.3 <0.05
Total bilirubin
(mg/dL)
5.4  6 1.4  0.9 <0.001
Conjugated
bilirubin (mg/dL)
3.8  4.4 0.7  0.7 <0.001
ALT, alanine amino transferase; AST, aspartate amino trans-
ferase; GGT, c-glutamyl transferase; ALP, alkaline phospha-
tase; IgG, immunoglobulin G; IgA, immunoglobulin A;
IgM, immunoglobulin M; PT, prothrombin time.
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During follow-up, seven patients received orthotopic
liver transplantation (OLTx) (9.5%), two in the group
with cirrhosis at presentation and five in the group
without cirrhosis. Indications for OLTx included hepa-
tocellular carcinoma (HCC) (in one patient and compli-
cations of portal hypertension in the remaining
patients). The mean time from the diagnosis of AIH to
transplant was 71.1  48.4 months. Figure 1 shows
the estimated probability of transplant in our popula-
tion (considering only 57 subjects < 65 years of age).
The cumulative transplant-free probability of survival
was 73.5% at 280 months.
Table 3. Clinical features of patients with type I AIH with
onset in geriatric age (> 65 years) and in adult life
(< 65 years) (mean  s.d.)
<65 years >65 years P-value
No. of patients 57 16 –
No. of patients
with acute
onset
16 (28%) 11 (68.7%) <0.05
Age (mean  s.d.) 42.0  14.0 73.0  5.0 –
Female (%) 89.9 86.7 –
Histological
findings* at
presentation
Mean grade 5.83  0.96 5.41  0.61 N.S.
Mean stage 4.62  1.08 5.47  0.62 <0.003
AST (U/L) 426.5  454.6 629.1  497.0 N.S.
ALT (U/L) 513.3  499.8 689.8  640.1 N.S.
GGT (U/L) 121.9  103.2 214.7  105.1 <0.01
ALP (U/L) 235.2  162.7 264.9  162.1 N.S.
IgG (mg/dL) 2239.9  984.8 2287.1  875.7 N.S.
IgA (mg/dL) 306.7  173.8 362.0  256.5 N.S.
IgM (mg/dL) 175.8  121.9 173.1  107.3 N.S.
PT (%) 73.6  17.6 69.5  16.8 N.S.
Serum
albumin (g/L)
36.5  5.2 34.3  7.5 N.S.
Total
bilirubin (mg/dL)
2.8  4.4 2.7  2.5 N.S.
Conjugated
bilirubin (mg/dL)
1.8  3.2 1.8  2.1 N.S.
* Maximum grade, 18; maximum stage, 6.
Table 4. Associated autoimmune conditions15
Autoimmune thyroid dysfunction (%) 17 (23.3)
Type I diabetes (%) 5 (6.8)
Sjogren’s syndrome (%) 3 (4.1)
Antiphospholipid syndrome (%) 1 (1.3)
Vitiligo (%) 1 (1.3)
Cryoglobulinaemia (%) 1 (1.3)
Autoimmune polyendocrine syndrome type III (%) 1 (1.3)
Coeliac disease (%) 1 (1.3)
Total (%) 30 (41)
Table 5. Obstetric and gynaecological features in patients
with AIH
63 women
No. of females with onset during pregnancy 4 (6.3 %)
No. of pregnancies before the onset 88/94 (93.6)
No. of pregnancies postdiagnosis of AIH 6/94 (6.4%)
Miscarriages preceding the diagnosis 11/13 (74.6%)
Miscarriages postdiagnosis 2/13 (15.4%)
Age of menarche (mean  s.d.) 12.8  1.6
Age of menopause (mean  s.d.) 49.7  4.1
No. of females with
abnormalities of menstrual cycle
13 (21.3%)
Table 6. Outcome of patients according to the presence
or absence of cirrhosis at presentation
Cirrhosis at
presentation
(n ¼ 28) (%)
No cirrhosis
at presentation
(n ¼ 45) (%)
All patients
(n ¼ 73) (%)
End points
Transplant 2 (7.1) 5 (11.1) 7 (9.5)
Oesophageal
varices
4 (14.3) 5 (11.1) 9 (12.3)
Ascites 2 (7.1) 2 (4.4) 4 (5.4)
HCC – 1 (2.2) 1 (1.4)
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Figure 1. Kaplan–Meier estimation for transplant curve
according to the disease in subjects <65 years of age.
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DISCUSSION
This multicentre Italian study is representative of a rel-
atively large series of type I AIH hepatitis patients
with a long-term follow-up. In general, the clinical
presentation of AIH in Italy is not different from other
series. Some clinical details, however, should be
stressed. First, 21.7% of patients with type I AIH are
older than 65 years at presentation. Moreover, patients
with acute onset have a significantly higher age than
those with chronic onset. This is in agreement with
other reports in which 17–56% cases of all patients
are over 65 years old at presentation.8, 11, 12, 1311 These
subjects most commonly presented with signs of acute
icteric hepatitis12 . Moreover, elderly patients have a
significantly higher frequency of cirrhosis at presen-
tation than adults, but the prognosis is excellent:
very few elderly patients with AIH have clinically
aggressive disease (overt jaundice, ascites and
encephalopathy). AIH should be considered in the
older patient, nonetheless, to avoid any delay in start-
ing immunosuppressive therapy. The higher staging
score found in elderly patients compared with adults is
in agreement with the recent report by Czaja et al.,8
who observed a greater frequency of cirrhosis at
presentation in elderly patients compared with the
group <30 years of age.
GGT serum levels were found significantly higher in
subjects > 65 compared with < 65 years, whereas no
significant difference in ALP was found between the
two groups. In other words, the increase in GGT does
not follow ALP. This finding is difficult to explain. A
possible explanation for the increase in GGT, at least
in part, could be the enzymatic induction in the
patients with the history of drug assumption before
the onset of AIH.
In fact, another point is the role of drugs as poten-
tial triggers. Certain drugs are known as triggers of
AIH1; however, nimesulide and trazodone have not
been associated with AIH previously. Nimesulide
toxicity has been widely associated with adverse
reactions of the liver, including increases in serum
aminotransferase activities, hepatocellular necrosis
and/or intrahepatic cholestasis.14 Drug-induced liver
toxicity from trazodone has also been reported,15
but data on the follow-up of patients are lacking. It
is notable, however, that the patient who developed
AIH after trazodone therapy experienced a severe
acute onset of AIH. Autoantibodies were negative
at that time, but both ANA and SMA became
positive after 4 weeks from the acute onset, and titre
increased to 1:320 and 1:1280, respectively, within
3 months. Similar to other drugs causing hepato-
toxicity, both the molecule and the patient contrib-
ute to the hazard. Genetic susceptibility of the patient
may be one of the factors that trigger autoimmunity.
The list of drugs considered as potential triggers for
AIH, however, can be longer, and it is advisable to
notify all adverse reactions of drugs to the National
Register.
We put particular emphasis on recording data con-
cerning menstrual abnormalities and the relationship
between pregnancy and AIH. We failed to observe
alterations in menstrual abnormalities and menopause
in our patients. Four females experienced the onset of
the disease during pregnancy, and the outcome in
such patients was favourable. The total number of
pregnancies was 93, six after achieving the remission.
The miscarriage rate of 15.4% is in agreement with the
previously reported data in the largest case series.16, 17
As previously reported,16 successful completion of
pregnancy is realistic expectation for patients with
well controlled AIH. A careful monitoring of preg-
nancy is, however, mandatory. No abnormalities in the
foetus were observed. We also failed to observe severe
flare-ups after delivery.18, 19
This study confirms that remission can be induced
and maintained in most AIH patients on the standard
corticosteroid-based immunosuppression used for sev-
eral decades. This is despite nearly 38.4% of our
cohort being cirrhotic at presentation, which is high
compared with 14% in another recent series of 89
patients,10 but is consistent with other data showing
that the presence of cirrhosis does not affect steroid
responsiveness.20 However, 7 of the 73 type I AIH
patients in our series required liver transplantation for
end-stage liver disease, two of whom were cirrhotic at
presentation and five did not present cirrhosis at the
initial biopsy. Another recent large series of 103
patients from a single centre in Germany found that
fewer patients (29%) had histological evidence of cir-
rhosis at presentation and no OLT was performed after
a mean observation period of 95 months.21 The overall
transplant rate during the follow-up is similar to that
observed by Feld et al. in Canada.9 These authors,
however, reported a significantly higher transplant rate
in subjects with cirrhosis (14.2%) compared with the
group without cirrhosis at presentation (1.2%). In our
experience, deterioration of liver disease is because
of the failure of immunosuppressive therapy, despite
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the presence of cirrhosis at initial biopsy. In a large
context, examining this issue, Roberts et al.22 came to
the same conclusion13 .
No deaths were recorded during follow-up. One
patient developed HCC and received liver transplant.
The cumulative transplant-free probability of survival
was 73.5% at 280 months, which is a good result, con-
sidering different types of liver disease.
In conclusion, with earlier diagnosis and improved
medical therapy, liver transplantation for AIH will
become a rare event in the future.
ACKNOWLEDGEMENTS14
This study was funded by grant of the MURST
National Research Programme.
REFERENCES
1 Krawitt EL. Autoimmune hepatitis. N
Engl J Med 2006; 354: 54–66.
2 Boberg KM, Aadland E, Jahnsen J, Rak-
nerud N, Stiris M, Bell H. Incidence and
prevalence of primary biliary cirrhosis,
primary sclerosing cholangitis and auto-
immune hepatitis in a Norwegian popu-
lation. Scand J Gastroenterol 1998; 33:
99–103.
3 Alvarez F, Berg PA, Bianchi FB, et al.
International autoimmune hepatitis
group report: review of criteria for diag-
nosis of autoimmune hepatitis. J Hepa-
tol 1999; 31: 929–38.
4 Czaja AJ. Drug therapy in the manage-
ment of type 1 autoimmune hepatitis.
Drugs 1999; 57: 49–68.
5 Heneghan MA, McFarlane IG. Current
and novel immunosuppressive therapy
for autoimmune hepatitis. Hepatology
2002; 357: 7–13.
6 Czaja AJ, Bianchi FB, Carpenter HA,
et al. Treatment challenges and investi-
gational opportunities in autoimmune
hepatitis. Hepatology 2005; 41: 207–15.
7 Johnson P, McFarlane IG, Williams R.
Azathioprine for long-term maintenance
of remission in autoimmune hepatitis. N
Engl J Med 1995; 333: 958–63.
8 Czaja AJ, Carpenter HA. Distinctive
clinical phenotype and treatment
outcome of type 1 autoimmune hepatitis
in the elderly. Hepatology 2006; 43:
532–8.
9 Feld JJ, Dinh H, Arenovich T, Marcus
VA, Wanless IR, Heathcote EJ. Autoim-
mune hepatitis: effect of symptoms and
cirrhosis on natural history and out-
come. Hepatology 2005; 42: 53–62.
10 Ishak K, Baptista A, Bianchi L, et al.
Histological grading and staging of
chronic hepatitis. J Hepatol 1995; 22:
696–9.
11 Newton JL, Burt AD, Park JB, Matthew
J, Bassendine MF, James OFW. Autoim-
mune hepatitis in older patients. Age
Ageing 1997; 26: 441–4.
12 Parker DR, Kingham JGC. Type I auto-
immune hepatitis is primarily a disease
of later life. Q J Med 1997; 90: 289–96.
13 Schramm C, Kanzler S, zum Buschen-
felde KH, Galle PR, Lohse AW. Autoim-
mune hepatitis in the elderly. Am J
Gastroenterol 2001; 96: 1587–91.
14 Boelsterli UA. Mechanisms of NSAID-
induced hepatotoxicity: focus on ni-
mesulide. Drug Saf 2002; 25: 633–48.
15 Conforti A, Leone R, Ghiotto E, et al.
Spontaneous reporting of drug-related
hepatic reactions from two Italian
regions (Lombardy and Veneto). Dig
Liver Dis 2000; 32: 16–23.
16 Heneghan MA, Norris SM, O’Grady JG,
Harrison PM, McFarlane IG. Manage-
ment and outcome of pregnancy in
autoimmune hepatitis. Gut 2001; 48:
97–102.
17 Schramm C, Herkel J, Beuers U, Kanzler
S, Galle PR, Lohse AW. Pregnancy in
autoimmune hepatitis: outcome and risk
factors. Am J Gastroenterol 2006; 101:
556–60.
18 Buchel E, Van Steenbergen W, Nevens
F, Fevery J. Improvement of autoim-
mune hepatitis during pregnancy fol-
lowed by flare-up after delivery. Am J
Gastroenterol 2002; 97: 3160–5.
19 Samuel D, Riordan S, Strasser S, Kurto-
vic J, Singh-Grewel I, Koorey D. Severe
autoimmune hepatitis first presenting in
early post partum period. Clin Gastroen-
terol Hepatol 2004; 2: 622–4.
20 Omagari K, Kinoshita H, Kato Y, et al.
Clinical features of 89 patients with
autoimmune hepatitis in Nagasaki Pre-
fecture, Japan. J Gastroenterol 1999;
34: 221–6.
21 Kanzler S, Lohr H, Gerken G, Galle PR,
Lohse AW. Long-term management and
prognosis of autoimmune hepatitis
(AIH): a single center experience. Z
Gastroenterol 2001; 39: 339–41.
22 Roberts SK, Therneau TM, Czaja AJ.
Prognosis of histological cirrhosis in
type I autoimmune hepatitis. Gastroen-
terology 1996; 110: 848–57.
AUTOIMMUNE HEPAT IT IS : A CL IN ICAL MULT ICENTRE STUDY 1057
ª 2006 The Authors, Aliment Pharmacol Ther 24, 1051–1057
Journal compilation ª 2006 Blackwell Publishing Ltd
